BIIB Share Price

Open 285.80 Change Price %
High 292.97 1 Day 4.24 1.49
Low 278.58 1 Week -7.65 -2.57
Close 289.54 1 Month -30.32 -9.48
Volume 4748741 1 Year 4.93 1.73
52 Week High 333.65
52 Week Low 223.02
BIIB Important Levels
Resistance 2 302.88
Resistance 1 297.38
Pivot 287.03
Support 1 281.70
Support 2 276.20
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 1.5
As on 8th Dec 2016 BIIB Share Price closed @ 289.54 and we RECOMMEND Buy for LONG-TERM with Stoploss of 279.76 & Sell for SHORT-TERM with Stoploss of 301.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for December
1st Target up-side 328.03
2nd Target up-side 351.65
3rd Target up-side 375.27
1st Target down-side 260.63
2nd Target down-side 237.01
3rd Target down-side 213.39
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.